Latest Breaking News On - Giiant pharma inc - Page 2 : comparemela.com

Palisade Bio Reports Third Quarter 2023 Financial Results

– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral.

United statesJenene thomasMitch jonesPalisade bio incCompany quarterly report on formExchange commissionCompany annual report on formKey programGiiant pharma incGiiant pharmaChief medical officerChief executiveFinancial resultsThird quarter ended septemberPalisade bioPrivate securities litigation reform act

Palisade Bio Inc (PALI) Enters Exclusive Worldwide Licensing Agreement with Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Palisade Bio Inc (PALI) Enters Exclusive Worldwide Licensing Agreement with Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristophe mellonGiiant pharmaJenene thomasGiiant pharma incColitis foundationPalisade bio incCompany annual report on formExchange commissionCompany quarterly report on formPalisade bioChief executive officerChief executivePrecision deliveryPrivate securities litigation reform actAnnual report

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJenene thomasGiiant pharmaChristophe mellonExchange commissionCompany quarterly report on formGiiant pharma incColitis foundationCompany annual report on formPalisade bio incChief executive officerPalisade bioChief executivePrecision deliveryPrivate securities litigation reform actAnnual report

Palisade Bio s stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies

Palisade Bio Inc.’s stock more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc..

Giiant pharma incPalisade bio incPalisade bioGiiant pharmaArticle normalCorporate industrial newsPalisade bio incS amp ampp 500 indexIndustrial news

Palisade Bio Transforms GI-Focused Pipeline Through

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing.

United statesGiiant pharmaChristophe mellonJenene thomasCompany annual report on formPalisade bio incCompany quarterly report on formColitis foundationExchange commissionGiiant pharma incChief executive officerPalisade bioChief executivePrecision deliveryPrivate securities litigation reform actAnnual report